CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07029399
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:14.256031+00:00
Published At: 2026-03-12T00:00:00+00:00
Record Updated At: 2026-03-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HR+ Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "CCNE1 Amplified Advanced Solid Tumors", "HR+ HER2- Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Uterine Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-12"
protocolSection.identificationModule.nctId: "NCT07029399"
protocolSection.identificationModule.officialTitle: "A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.